Role of chemotherapy in relapsed ovarian cancer

被引：16

作者：

Colombo, N ^{[1
]}

Parma, G ^{[1
]}

Bocciolone, L ^{[1
]}

Sideri, M ^{[1
]}

Franchi, D ^{[1
]}

Maggioni, A ^{[1
]}

机构：

[1] European Inst Oncol, Div Gynecol, Milan, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 1999年 / 32卷 / 03期

关键词：

D O I：

10.1016/S1040-8428(99)00049-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：221 / 228

页数：8

共 54 条

[1]

AAPRO M, 1993, P AN M AM SOC CLIN, V12, P256

[2]

ABURUSTUM NR, 1997, SEMIN ONCOL S15, V24, pS1562

[3] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[4]

ARMSTRONG D, 1995, P AN M AM SOC CLIN, V14, P275

[5]

BAJETTA E, 1996, J CLIN ONCOL, V14, P2446

[6] RESPONSE OF PATIENTS IN PHASE-II STUDIES OF CHEMOTHERAPY IN OVARIAN-CANCER - IMPLICATIONS FOR PATIENT TREATMENT AND THE DESIGN OF PHASE-II TRIALS [J].

BLACKLEDGE, G ;

LAWTON, F ;

REDMAN, C ;

KELLY, K .

BRITISH JOURNAL OF CANCER, 1989, 59 (04) :650-653

[7] Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].

Boehm, T ;

Folkman, J ;

Browder, T ;

OReilly, MS .

NATURE, 1997, 390 (6658) :404-407

[8]

*BRIST MYERS SQUIB, 1996, TAX PACL INJ CONC

[9] Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer [J].

Burger, RA ;

DiSaia, PJ ;

Roberts, JA ;

O'Rourke, M ;

Gershenson, DM ;

Homesley, HD ;

Lichtman, SM ;

Barnes, W ;

Moore, DH ;

Monk, BJ .

GYNECOLOGIC ONCOLOGY, 1999, 72 (02) :148-153

[10]

Chollet P, 1996, ANN ONCOL, V7, P1065

← 1 2 3 4 5 6 →